Differential inducibility of p53-downstream genes in human neuroblastoma cell lines

Journal of the Medical Society of Toho University

Volumn 50, Issue 1, 2003, Pages 13-23

  Sugiyama, Hisahiko ^a   Arita, Michitsune ^a   Zhong, Xioling ^a   Min, Zhenghua ^a   Hemmi, Hiromichi ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bax; mdm2; Neuroblastoma cells; p21; p53; Posttranslational modification; Reporter gene assay

Indexed keywords

DOXORUBICIN; LUCIFERASE; PHOSPHOPROTEIN; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER GENETICS; CELL CULTURE; DNA SEQUENCE; GENE CONSTRUCT; GENE CONTROL; GENE MUTATION; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MISSENSE MUTATION; NEUROBLASTOMA; OSTEOSARCOMA; PLASMID; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; TUMOR SUPPRESSOR GENE;

EID: 0037228785     PISSN: 00408670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Tsuchida Y, Hemmi H, Inoue A, Obana K, Yang HW, Hayashi Y, Kanda N, Shimatake H: Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: Amplified or not amplified? -An overview. Tumour Biol 17: 65-74, 1996
2. Suita S, Zaizen Y, Kaneko M, Uchino J, Takeda T, Iwafuchi M, Utsumi J, Takahashi H, Yokoyama J, Nishihira H, Okada A, Kawa K, Nagahara N, Yano H, Tsuchida Y: What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma. J Pediatr Surg 29: 746-750, 1994
3. Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H, Castleberry RP, Bowman LC, Rao PV, Seeger RC, Brodeur GM: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 55: 721-726, 1995
4. Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G: Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81: 1401-1405, 1989
5. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Crossman J, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989
6. Bader P, Schilling F, Schlaud M, Girgert R, Handgretinger R, Klingebiel T, Treuner J, Liu C, Niethammer D, Beck JF: Expression analysis of multidrug resistance associated genes in neuroblastomas. Oncol Rep 6: 1143-1146, 1999
7. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036-5040, 1994
8. Matsunaga T, Shirasawa H, Hishiki T, Enomoto H, Kouchi K, Ohtsuka Y, Iwai J, Yoshida H, Tanabe M, Kobayashi S, Asano T, Etoh T, Nishi Y, Ohnuma N: Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior. Jpn J Cancer Res 89: 1276-1283, 1998
9. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP: p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 35: 563-568, 2000
10. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J: Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61: 8-13, 2001
11. Fields S, Jang SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1049, 1990
12. Raycroft L, Wu HY, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049-1051, 1990
13. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
14. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993
15. Smith ML, Chen I-T, Zhan Q, Bae I, Chen C-Y, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380, 1994
16. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992
17. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995
18. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995
19. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993
20. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M: A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23: 2584-2592, 1995
21. Degtyareva N, Subramanian D, Griffith JD: Analysis of the binding of p53 to DNAs containing mismatched and bulged bases. J Biol Chem 276: 8778-8784, 2001
22. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996
23. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
24. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997
25. Jimenez GS, Khan SH, Stommel JM, Wahl GM: p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18: 7656-7665, 1999
26. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991
27. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53: 5269-5273, 1993
28. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, Hanada R, Yamamoto K, Hongo T, Yamada M, Tsuchida Y: Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53: 5284-5288, 1993
29. Castresana JS, Bello MJ, Rey JA, Nebreda P, Queizan A, Garcia-Miguel P, Pestana A: No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosomes Cancer 10: 136-138, 1994
30. Sekiguchi M, Oota T, Sakakibara K, Inui N, Fujii G: Establishment and characterization of a human neuroblastoma cell line in tissue culture. Jpn J Exp Med 49: 67-83, 1979
31. Brodeur GM, Sekhon G, Goldstein MN: Chromosomal aberrations in human neuroblastomas. Cancer 40: 2256-2263, 1977
32. Hemmi H, Yamada K, Yoon UH, Kato M, Taniguchi F, Tsuchida Y, Shimatake H: Coexpression of the myc gene family members in human neuroblastoma cell lines. Biochem Mol Biol Int 36: 1135-1141, 1995
33. Chen P-L, Chen Y, Bookstein R, Lee W-H: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1990
34. Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H: Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 49: 438-444, 2002
35. Thornborrow EC, Manfredi JJ: One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 274: 33747-33756, 1999
36. Thornborrow EC, Manfredi JJ: The tumor suppressor protein p53 requires a cofactor to activate transcriptionally the human BAX promoter. J Biol Chem 276: 15598-15608, 2001
37. (WAF1/CIP1) gene. Exp Cell Res 246: 280-289, 1999
38. ARF. Cell 103: 321-330, 2000
39. Butt AJ, Firth SM, King MA, Baxter RC: Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275: 39174-39181, 2000
40. Yonezawa M, Otsuka T, Kato T, Moriyama A, Kato KH, Asai K, Matsui N: Hyperthermic induction of apoptosis in malignant fibrous histiocytoma cells: possible involvement of a p53-independent pathway in the induction of bax gene. J Orthop Sci 7: 117-122, 2002
41. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002
42. Goldman SC, Chen C-Y, Lansing TJ, Gilmer TM, Kastan MB: The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 148: 1381-1385, 1996
43. Jia LQ, Osada M, Ishioka C, Gamo M, Ikawa S, Suzuki T, Shimodaira H, Niitani T, Kudo T, Akiyama M, Kimura N, Matsuo M, Mizusawa H, Tanaka N, Koyama H, Namba M, Kanamaru R, Kuroki T: Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19: 243-253, 1997
44. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD: Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17: 1847-1859, 1998
45. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757, 1978
46. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405, 1998
47. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312, 1994
48. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M: Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721-3725, 1995